Last Array of Hope - COVID-19 Convalescent Plasma Therapy

-
Image
A pilot trial of convalescent plasma treatment in 10 extreme COVID-19 patients has indicated it might be a protected and promising helpful choice. M ore than fifteen Indian states and Union Territories represent over 95% of the total coronavirus cases in the nation. Amongst them, 33% of the  cases are reported in Maharashtra and Tamil Nadu, which are speeding up lately. Economic times surveys the information, which recommends that a portion of the 15 states/UTs need to put forth a more noteworthy attempt to flatten the curve. Source: WWW.MoHFW.gov Coronavirus disease is an infectious pneumonia-related severe respiratory illness. The official name, Coronavirus disease 2019 which is also called COVID-19 was given by the world health organization (WHO), and the first case of this disease was reported in Wuhan, China.  The scourge spread quickly all around the world within 3 months and has been declared as a pandemic by WHO on March 11, 2020. As of April 13...
Post a Comment

Type 2 diabetes: Progressing novel scientific insight into new medicine

-

The gap in the long process of progressing a novel scientific insight into a new medicine is often called “the valley of death”. Read below to understand how the strategic alliance between University of Oxford and Novo Nordisk is aiming to combat type 2 diabetes by bridging this gap

The gap between translating basic research discoveries into medicines is often called “the valley of death”. The process of progressing a novel scientific insight into a new medicine is long, challenging, labour-intensive and expensive and all too often exciting ideas are lost along the way. The strategic alliance between the University of Oxford and Novo Nordisk aims to bridge that gap, by marrying leading academic science with the best of pharmaceutical research and development capabilities.

Fuelled by an obesity pandemic, type 2 diabetes affects more than 379 million people1 and is today the fastest-growing chronic disease on a global level2. It is this challenge that research in the alliance between the University of Oxford and the Novo Nordisk Research Centre Oxford (NNRCO) aims to address. Since the NNRCO was announced in January 2017, the stated ambition is to enable scientists from Novo Nordisk and the University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes.
The total investment from Novo Nordisk is expected to be around 1 billion Danish kroner (115 million British pounds) over a period of 10 years3. The centre focuses on the early-stage innovation that often falls in the “valley” between fundamental insights and clinical development. It aims to have a substantial impact on the future treatment of type 2 diabetes and its complications. But what makes the collaboration unique? The answer lies in bringing the right translational research insights into a strong collaboration between academia and industry.

Bringing hope for patients

It is cross-fertilisation between academia and pharma that is the ultimate goal of the NNRCO, which by many is called ‘a hybrid institute’. To date, it employs 20 researchers who are already involved in research projects together with colleagues from Oxford University. Interim site head of the NNRCO, Allan Ertmann Karlsen says: “I am very motivated by the activities that we see here at the research centre every day. Being able to bring excellent fundamental scientists from the University of Oxford together with experienced researchers and clinicians from Novo Nordisk to translate their findings into tangible ideas for further development brings increased hope for patients”

Location: India

Comments

Post a Comment

Popular posts from this blog

Last Array of Hope - COVID-19 Convalescent Plasma Therapy

-
Image
A pilot trial of convalescent plasma treatment in 10 extreme COVID-19 patients has indicated it might be a protected and promising helpful choice. M ore than fifteen Indian states and Union Territories represent over 95% of the total coronavirus cases in the nation. Amongst them, 33% of the  cases are reported in Maharashtra and Tamil Nadu, which are speeding up lately. Economic times surveys the information, which recommends that a portion of the 15 states/UTs need to put forth a more noteworthy attempt to flatten the curve. Source: WWW.MoHFW.gov Coronavirus disease is an infectious pneumonia-related severe respiratory illness. The official name, Coronavirus disease 2019 which is also called COVID-19 was given by the world health organization (WHO), and the first case of this disease was reported in Wuhan, China.  The scourge spread quickly all around the world within 3 months and has been declared as a pandemic by WHO on March 11, 2020. As of April 13...
Read more

3D Bioprinting-Theortical Insight & Success Stories

-
A s I discussed Introductory part and some benefits of 3D-Bioprinting in the previous blog now I would like to emphasis of the Central approaches of  3D-bioprinting in Medical. So, Lets begin with three central approaches to bioprinting are biomimicry, autonomous self-assembly, and a microtissue-based method. These general strategies are not exclusive to bioprinting and are broadly applied to many investigational areas within the larger scope of regenerative medicine. In many cases, these are used for tissue engineering applications unrelated to bioprinting. However, a discussion of these fundamental strategies is necessary when considering the optimal approach to bioprinting objectives. Each of these may applied to specific bioprinting applications to varying degrees based on factors such as target tissue type, user experience, and printing method. It is not uncommon to combine strategies for more complex tissue types. I would to discuss each of these in detail below. With the...
Read more